Lyell Immunopharma (LYEL) Return on Equity (ROE)

Price: $0.467
Market Cap: $137.92M
Avg Volume: 1.00M
Country: US
Industry: Biotechnology
Sector: Healthcare
Beta: -0.27
52W Range: $0.393-2.875
Website: Lyell Immunopharma

Return on Equity (ROE) Summary

Lyell Immunopharma's ROE measures the return generated on shareholders' equity:

  • Annual: -89.60%
  • Quarterly: -50.14%
  • TTM: -65.86%

What is Return on Equity (ROE)?

Return on Equity measures a company's ability to generate profits from its shareholders' equity. It indicates how effectively the management is using the company’s assets to create profits. A higher ROE generally reflects well on the company’s management and its ability to generate profits without needing as much capital.

Related Metrics

Other important metrics to assess Lyell Immunopharma's profitability include:

  • ROIC (Return on Invested Capital) - measures how effectively the company uses its invested capital to generate profits:
    • Annual: -0.76%
    • Quarterly: -45.20%
    • TTM: -82.31%
  • ROA (Return on Assets) - measures the return generated on the company's assets:
    • Annual: -69.88%
    • Quarterly: -39.10%
    • TTM: -69.88%
  • Profit Margin - indicates the profitability of the company relative to its revenue:
    • Annual: -562285.25%
    • Quarterly: -1744863.64%
    • TTM: -562285.25%

These metrics provide insights into Lyell Immunopharma's profitability and efficiency in using its capital and assets to generate returns. Comparing these ratios with industry benchmarks can offer a deeper understanding of the company's performance.

Annual ROE

-89.60%

Quarterly ROE

-50.14%

TTM ROE

-65.86%

Lyell Immunopharma Historical ROE
0.00%0.00%-17.92%-17.92%-35.84%-35.84%-53.76%-53.76%-71.68%-71.68%-89.60%-89.60%ROE202020202021202120222022202320232024202420252025
Historical ROIC
0.00%0.00%-6.84%-6.84%-13.69%-13.69%-20.53%-20.53%-27.38%-27.38%-34.22%-34.22%ROIC202020202021202120222022202320232024202420252025
Historical ROA
0.00%0.00%-13.98%-13.98%-27.95%-27.95%-41.93%-41.93%-55.90%-55.90%-69.88%-69.88%ROA202020202021202120222022202320232024202420252025

Lyell Immunopharma Historical Profitability Metrics

The table below shows various profitability metrics for each year, with the latest data available for the last fiscal year 2024.

Year ROE ROIC ROA Profit Margin
2024 -89.60% -0.76% -69.88% -562285.25%
2023 -35.82% -34.22% -31.28% -180486.15%
2022 -0.57% -0.53% -0.51% -5.61%
2021 -30.71% -22.65% -25.32% -2680.76%
2020 -27.63% -23.86% -21.86% -2559.73%
2019 -29.72% -17.92% -21.82% -18456.01%

Related Metrics

Explore detailed financial metrics and analysis for LYEL.